Abstract
Importance:Cerebralvenoussinusthrombosis(CVST)withthrombocytopenia,arareandseriouscondition,hasbeendescribedinEuropefollowingreceiptoftheChAdOx1nCoV-19vaccine(Oxford/AstraZeneca),whichusesachimpanzeeadenoviralvector.Amechanismsimilartoautoimmuneheparin-inducedthrombocytopenia(HIT)hasbeenproposed.IntheUS,theAd26.COV2.SCOVID-19vaccine(Janssen/JohnsonJohnson),whichusesahumanadenoviralvector,receivedEmergencyUseAuthorization(EUA)onFebruary27,.ByApril12,,approximately7millionAd26.COV2.SvaccinedoseshadbeengivenintheUS,and6casesofCVSTwiththrombocytopeniahadbeenidentifiedamongtherecipients,resultinginatemporarynationalpauseinvaccinationwiththisproductonApril13,.
Objective:TodescribereportsofCVSTwiththrombocytopeniafollowingAd26.COV2.Svaccinereceipt.
Design,setting,andparticipants:Caseseriesof12USpatientswithCVSTandthrombocytopeniafollowinguseofAd26.COV2.SvaccineunderEUAreportedtotheVaccineAdverseEventReportingSystem(VAERS)fromMarch2toApril21,(withfollow-upreportedthroughApril21,).
Exposures:ReceiptofAd26.COV2.Svaccine.
Mainout
转载请注明地址:http://www.bfmcc.com/zcmbjc/16743519.html
